GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
T

Tauns Laboratories 197A.T · JPY

N/A · Tokyo Stock Exchange · 🇯🇵 Japan

Compare

481

+1.05%

Close of 9 Nov 2026, in JPY

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About Tauns Laboratories

Its shares trade on Tokyo Stock Exchange under the ticker 197A.T. It has been listed since 20 June 2024. In the fiscal year to 30 June 2026, it reported revenue of ¥14.37bn and net income of ¥5.50bn. At that date it held total assets of ¥44.62bn and shareholders' equity of ¥19.42bn.

Tauns Laboratories Inc is a JP-based company operating in industry. The company is headquartered in Izunokuni-Shi, Shizuoka-Ken. The company went IPO on 2024-06-20. Tauns Laboratories Inc is a Japan-based company engaged in the business of developing, manufacturing and marketing in vitro diagnostic products and research reagents. The firm operates its business in the in vitro diagnostic products business segment. The Company’s main product is antigen test kit that uses immunochromatography to enable rapid diagnosis at the patient's side without the need for special equipment. The products include ImunoAce Flu, ImunoAce SARSCoV-2 II, ImunoAce SARSCoV-2 Saliva, ImunoAce SARSCoV-2/Flu, ImunoAce Adeno, ImunoAce Strep A Neo, ImunoAce hMPV, ImunoAce Mycopiasma, ImunoAce RSV Neo and ImunoAce Noro.

Figures and description from our data supplier, not checked against the company's own report.

Company facts

Sector
N/A
Industry
N/A
Listed since
20 Jun 2024
Employees
243
Website
tauns.co.jp ↗

Leadership

Pay as last reported

  • Mr. Masaki NonakaPresident, Chief Executive Officer, Representative Director, since 2023

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
0
Environment
0
Social
0
Governance
0

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • Tauns Laboratories Inc develops antigen test kits for rapid diagnosis without special equipment.
  • ImunoAce Flu and ImunoAce SARSCoV-2 II are key products in the in vitro diagnostic segment.
  • The company employs 243 full-time staff in Izunokuni-shi, Shizuoka-Ken.

Weaknesses

  • The company has only one business segment focused on in vitro diagnostic products.
  • Tauns Laboratories Inc is a newly listed company with IPO on 20 June 2024.
  • Izunokuni-shi, Shizuoka-Ken is a small city with limited industry presence.

Opportunities

  • The global demand for rapid diagnostic products is increasing in the Health Care sector.
  • ImunoAce SARSCoV-2 Saliva and ImunoAce RSV Neo can expand into new markets.
  • Japan's healthcare system supports growth in diagnostic product adoption.

Threats

  • The in vitro diagnostic market faces competition from established firms in the Health Care sector.
  • Regulatory changes in Japan could impact the approval of diagnostic products.
  • Economic downturns may reduce healthcare spending on diagnostic tools.

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.